CoChat

A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity

Open access
Shono, Yusuke, Tuckett, Andrea Z., Ouk, Samedy, Liou, Hsiou-Chi, Altan-Bonnet, Grégoire, Tsai, Jennifer J., Oyler, Jennifer E., Smith, Odette M., West, Mallory L., Singer, Natalie V., Doubrovina, Ekaterina, Pankov, Dmitry, Undhad, Chandresh V., Murphy, George F., Lezcano, Cecilia, Liu, Chen, O'Reilly, Richard J., van den Brink, Marcel R.M., Zakrzewski, Johannes L. · 2014 · Cancer Discovery
Cited by 58

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Preventing unfavorable GVHD without inducing broad suppression of the immune system presents a major challenge of allogeneic hematopoietic stem cell transplantation (allo-HSCT). We developed a novel strategy to ameliorate GVHD while preserving graft-versus-tumor (GVT) activity by small molecule–based inhibition of the NF-κB family member c-Rel. Underlying mechanisms included reduced alloactivation, defective gut homing, and impaired negative feedback on interleukin (IL)-2 production, resulting in optimal IL-2 levels, which, in the absence of competition by effector T cells, translated into expansion of regulatory T cells. c-Rel activity was dispensable for antigen-specific T-cell receptor (TCR) activation, allowing c-Rel–deficient T cells to display normal GVT activity. In addition, inhibition of c-Rel activity reduced alloactivation without compromising antigen-specific cytotoxicity of human T cells. Finally, we were able to demonstrate the feasibility and efficacy of systemic c-Rel inhibitor administration. Our findings validate c-Rel as a promising target for immunomodulatory therapy and demonstrate the feasibility and efficacy of pharmaceutical inhibition of c-Rel activity. Significance: Chemical inhibition of c-Rel diminishes alloactivation while preserving antigen-specific TCR activation, revealing the redundancy of c-Rel in T cell–mediated antitumor activity of both mouse and human T cells. Our study provides a highly innovative immunomodulatory approach that has true potential for drug development and clinical application with broad therapeutic implications, including allo-tolerance induction after allo-HSCT, as well as antitumor therapies. Cancer Discov; 4(5); 578–91. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 495

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0585

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 58

Metadata

Authors
Shono, Y., Tuckett, A. Z., Ouk, S., Liou, H.-C., Altan-Bonnet, G., Tsai, J. J., Oyler, J. E., Smith, O. M., West, M. L., Singer, N. V., Doubrovina, E., Pankov, D., Undhad, C. V., Murphy, G. F., Lezcano, C., Liu, C., O'Reilly, R. J., van den Brink, M. R. M., & Zakrzewski, J. L.
Venue
Cancer Discovery
Published
2014-05-01
Volume
4
Issue
5
Pages
578-591
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2151117422
Cited by
58
References
2
FWCI
4.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0585
The paper
Shono, Y., Tuckett, A. Z., Ouk, S., Liou, H.-C., Altan-Bonnet, G., Tsai, J. J., Oyler, J. E., Smith, O. M., West, M. L., Singer, N. V., Doubrovina, E., Pankov, D., Undhad, C. V., Murphy, G. F., Lezcano, C., Liu, C., O'Reilly, R. J., van den Brink, M. R. M., & Zakrzewski, J. L. (2014). A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0585

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.